17 January 2022 - News Deck

Akseera Pharma Corp – The Company behind CBD for COVID

17 January 202217 January 2022 Vijay Raman

MUMBAI, India, Jan. 17, 2022 /PRNewswire/ — Akseera Pharma Corp., a Canadian company, is leading the research surrounding CBD and COVID-19. Specifically, they have collaborated with premier universities studying the potential of CBD as a therapeutic. Akseera has been scientifically investigating the medicinal benefits of synthetic Cannabinoids since 2016. These research projects have shown the huge untapped potential in various unmet healthcare needs, including prevention and prophylaxis of COVID-19. Prof. Robin Duncan, the lead investigator at the University of Waterloo, explains that even before the immune system notices a virus is…

Goa Eyes Investment Opportunities from India Pavilion

17 January 202217 January 2022 Vijay Raman

The smallest state of India is emerging as one of the fastest-growing with its business-friendly policies Dubai, United Arab Emirates The state of Goa is ready to showcase its tourism prowess and business opportunities available in the state to global investors during its participation at India Pavilion in EXPO2020 Dubai. Dr. Aman Puri, Consul General of India in Dubai and Mr. J Ashok Kumar, Secretary, Industries & Tourism, Government of Goa at the Goa Week inauguration ceremony at India Pavilion, EXPO2020 held yesterday The state’s floor was inaugurated yesterday by…

Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe

17 January 202217 January 2022 Vijay Raman

MUMBAI, India, Jan. 17, 2022 /PRNewswire/ — Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the generic version of Lexiscan®1 Injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US, Inc. According to IQVIATM sales data for the 12 month period ending November 2021, the Lexiscan® Injection, 0.4 mg/5 mL (0.08 mg/mL) market2 achieved annual sales of approximately $659.9 million.* Glenmark’s current portfolio consists of 172 products authorized for distribution in the…